文献速递临床试验与 GCP真实世界研究与卫生经济

PARTIAL研究方案:复杂T1肾细胞癌部分与根治性肾切除术的临床与成本效果随机试验

PARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trial.
PubMed 文献 · Trials · 2026-03-20

PARTIAL是一项在英国NHS中心开展的实用型随机对照优效性试验,计划招募420例单发T1肾细胞癌、对侧肾功能正常且多学科团队认为适合微创部分或根治性肾切除术的成人患者,1:1随机分组。主要结局为2年肾功能保护获益和围手术期手术并发症,旨在明确复杂T1肾肿瘤中部分肾切除术是否优于根治性肾切除术并抵消其潜在危害与成本。

要点

  • 复杂T1肾肿瘤(外生性T1a、T1b或内生性T1a)中部分肾切除术的获益尚不明确。
  • 试验比较部分与根治性肾切除术,主要结局为2年肾功能保护和围手术期并发症。
  • 若部分肾切除术无显著获益且并发症过多,可能支持根治性肾切除术作为标准治疗。

核心结论

  • PARTIAL试验将确定复杂T1肾肿瘤中部分肾切除术的获益是否优于根治性肾切除术并抵消潜在危害与成本。
  • 若部分肾切除术未显示临床显著获益且并发症过多得到证实,可能支持根治性肾切除术作为标准治疗。

研究设计与样本

  • 实用型随机对照平行组非盲优效性试验,嵌入内嵌试点、经济评价和过程评价。
  • 计划在英国NHS中心招募420例参与者,这些中心具备微创肾切除术技术专长。
  • 符合条件的知情同意成人随机1:1接受部分肾切除术或根治性肾切除术。

关键数值与推荐

  • 纳入标准:单发T1肾细胞癌、对侧肾功能正常、多学科团队确认适合两种微创干预。
  • 排除标准:转移性疾病、现有慢性肾病、孤立功能肾、先天性肾异常、遗传性肾癌综合征、无知情同意能力、妊娠或哺乳。
  • 主要结局:2年肾功能保护获益和围手术期手术并发症。
  • 次要结局:生活质量和恢复、成本和成本效果、切缘阳性率、复发和心血管事件、总生存、进展至慢性肾病和终末期肾衰竭、中转开放手术和患者可接受性。
  • 随访2年,结局从医疗记录和患者问卷收集。

临床怎么用

  • 为复杂T1肾肿瘤选择部分或根治性肾切除术提供高质量随机证据。
  • 结果可能改变复杂T1肾肿瘤的临床实践标准。

局限性

  • 非盲设计可能影响患者报告结局和部分临床决策。
  • 试验仅在英国NHS中心开展,外推性需考虑医疗体系差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Localised renal cell carcinoma is treated with radical nephrectomy (RN) or partial nephrectomy (PN). Nephron-sparing PN increases preservation of renal function, reducing incidence of end stage renal failure and associated cardiovascular events. In patients with exophytic T1a (≤ 4 cm) tumours and normal contralateral kidney, PN is standard of care. In patients with T1b (> 4-7 cm) or endophytic T1a tumours and normal contralateral kidney, the benefits of PN over RN are less clear as there are increased surgical complications and more tissue may be excised reducing the preservation of renal function. There are no high-quality studies to address if PN is superior to RN in these more complex cases. METHODS: PARTIAL is a pragmatic randomised controlled parallel group unblinded superiority trial with embedded internal pilot and economic and process evaluation. A total of 420 participants will be recruited in UK NHS centres with expertise in minimally invasive nephrectomy techniques. Eligible consenting adults with a single T1 renal cell carcinoma, normal contralateral kidney and equipoise within the multidisciplinary team confirming suitability to receive both interventions by minimally invasive approaches are randomised 1:1 to PN or RN. Patients with metastatic disease, existing chronic kidney disease, solitary functioning kidney, congenital renal abnormality, inherited kidney cancer syndrome, who lack capacity to consent or are pregnant or breast feeding are excluded. Primary outcomes are gains in preservation of renal function at 2 years and surgical complications over the peri-operative period. Secondary outcomes are quality of life and recovery, cost and cost-effectiveness, rates of positive surgical margin, recurrence and cardiovascular events, overall survival, progression to chronic kidney disease and end stage renal failure, operative conversion and patient acceptability. Participants are followed up for 2 years with outcomes collected from medical records and participant questionnaires. DISCUSSION: PARTIAL will determine if gains from PN are superior to RN and offset the potential harms and costs in complex T1 renal tumours suitable for either approach. If PN is not found to provide clinically significant gains and excess complications are confirmed, then a practice-changing case for RN as standard of care could be made. TRIAL REGISTRATION: ISRCTN 11293415. Registered prospectively on 19 January 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Johnson D, Thomas R, Cotton S, et al. PARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trial. Trials. 2026. PMID: 41863008. doi:10.1186/s13063-026-09624-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。